In this episode of Medtech Matters, a podcast focused on the medical device manufacturing industry and the factors impacting it, we speak with Peter Vranes, co-founder and co-CEO of the Australian company Nutromics. He offers insight on a platform technology that enables continuous molecular monitoring. Using continuous glucose monitoring as an example for the potential for the technology, Vranes explains how his technology is capable of tracking any target, not just glucose. Specifically, the following questions are addressed.

• Your company has developed a continuous molecular monitoring platform. What does that mean exactly?
• Most people are aware of why you need to monitor glucose especially for diabetics but why seek to measure anything other than glucose continuously?
• How is your technology different from continuous glucose monitors already on the market?
• What is your first intended market for the technology and why did you choose it?
• Does the platform lend itself to be expanded to monitor other items such as white blood cell count or perhaps a disease?
• You’re developing a smart patch to serve as a carrier for the platform. When are you looking to launch that and what will the functions of the patch be?
• Is this technology only suitable for in hospital use?

Listen to this episode and see what you think of this platform for continuous molecular monitoring. If you’d like to share thoughts, ask questions, or suggest a future participant for Medtech Matters, please reach out to me at [email protected].

Listen to the podcast streaming via the player or get the podcast on the Medtech Matters channel via your preferred vendor of podcasts, such as Apple Podcasts (iTunes) or Spotify.

Send us a text

For more medtech news and information, visit www.mpomag.com.